Key statistics
As of last trade Climb Bio Inc (CLYM:NMQ) traded at 5.23, -10.75% below its 52-week high of 5.86, set on Feb 10, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.56 |
|---|---|
| High | 5.56 |
| Low | 5.06 |
| Bid | 5.22 |
| Offer | 5.24 |
| Previous close | 5.56 |
| Average volume | 521.01k |
|---|---|
| Shares outstanding | 68.18m |
| Free float | 67.64m |
| P/E (TTM) | -- |
| Market cap | 379.11m USD |
| EPS (TTM) | -0.7507 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 20:06 GMT.
More ▼
Announcements
- Climb Bio to Present at Upcoming Investor Conferences
- Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
- Climb Bio to Present at Upcoming Investor Conferences
- Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
- Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
- Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
- Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
- Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
More ▼
